Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goal-oriented upfront combination therapy to preserve right ventricular function in pulmonary arterial hypertension
NL-OMON40011Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2013
- Countries
- 1
01
Overview
Open-label, single-arm trial in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy and Heritable Pulmonary Arterial Hypertension (HPAH), sponsored by Vrije University Medical Center. Primary endpoint: Preservation or improvement of right ventricular ejection fraction. Started May 2013; status: active, not recruiting.
02
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on NL-OMON40011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40011.